anti- MTM1 antibody
Background:
Lipid phosphatase which dephosphorylates phosphatidylinositol 3-monophosphate(PI3P) and phosphatidylinositol 3,5-bisphosphate(PI(3,5)P2). Has also been shown to dephosphorylate phosphotyrosine-and phosphoserine-containing peptides. Negatively regulates EGFR degradation through regulation of EGFR trafficking from the late endosome to the lysosome. Plays a role in vacuolar formation and morphology. Regulates desmin intermediate filament assembly and architecture. Plays a role in mitochondrial morphology and positioning. Required for skeletal muscle maintenance but not for myogenesis.
Clonality:
polyclonal
Classification:
Primary antibody
Alternative names:
CG2
Specificity:
Human, Mouse, Rat
Host:
Rabbit
Isotype:
IgG
Immunogen:
myotubularin 1
Purification:
Immunogen affinity purified
Purity:
≥95% as determined by SDS-PAGE
Calculated molecular weight:
63 kDa
Form:
liquid
Applications:
ELISA, WB, IHC
Recommended dilution:
Request info at info@sobekbio.com
Storage:
PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
More info:
Email: info@sobekbio.com
Orders:
Email: orders@sobekbio.com
Fine Biotech is an ISO9001:2008 Certified Company,offers a full line of quality research kits,which include ELISA Kits,related ELISA assistant reagents and more high quality antibodies, recombinant proteins. Fine Biotech technical support are delicated to providing with professional and friendly assistance for our customers. Strict and multiple quality control ensure that our products continue to successfully supply for the international market. Moreover, we strive to continuously improve the customer experience through comprehensive technical support. High quality,rapid turnaround and personal support for all FineTest services are guaranteed. Should you have any problems,or any ideas on ways that we can improve our service,please feel free to call upon us.Thank you for your interest in FineTest products and we look forward to supplying you in the near future.